论文部分内容阅读
40例43～73岁(平均58岁)慢性阻塞性肺部疾病、消化道疾病、高血压、心血管疾病或糖尿病等慢性疾病患者参加了试验,其中13人鼻腔接种甲型流感冷适应-重组疫苗CR37[A/加利福尼亚/10/78(H1N1)],27人鼻腔接种甲型流感冷适应重组疫苗CR48[A/华盛顿/897/80(H3N2)]。接种后第1～5、7、14和28天观察与疫苗接种有关的症状和体征,结果表明接种疫苗后未见临床发病及肺功能降低。疫苗接种前及接种后第1～5天和第7天采取鼻洗液标本,进行病毒分离。接种CR37(H1N1)疫苗者病毒分离均为阴性;2名接种
Forty patients with chronic obstructive pulmonary disease, gastrointestinal diseases, hypertension, cardiovascular disease or diabetes mellitus aged from 43 to 73 years (average 58 years) participated in the trial. Among them, 13 patients received nasal influenza A cold acclimation-recombination Vaccine CR37 [A / California / 10/78 (H1N1)], nasal cavity inoculation with influenza A influenza CR48 [A / Washington / 897/80 (H3N2)]. Symptoms and signs associated with the vaccination were observed 1 to 5, 7, 14 and 28 days after inoculation. The results showed no clinical onset or reduced lung function after vaccination. Nasal wash samples were taken before vaccination and on days 1 to 5 and 7 after inoculation for virus isolation. Inoculation of CR37 (H1N1) vaccine virus were negative; 2 inoculation